✦ LIBER ✦

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

✍ Scribed by Ebb, D.; Meyers, P.; Grier, H.; Bernstein, M.; Gorlick, R.; Lipshultz, S. E.; Krailo, M.; Devidas, M.; Barkauskas, D. A.; Siegal, G. P.; Ferguson, W. S.; Letson, G. D.; Marcus, K.; Goorin, A.; Beardsley, P.; Marina, N.

Book ID: 119938365
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 180 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2011.37.4546

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

Multicenter Phase II Trial of Neoadjuvan

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

✍ Glück, S. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Robert, N. J.; Dieras, V.; Glaspy, J.; Brufsky, A. M.; Bondarenko, I.; Lipatov, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 317 KB